SG11202000549TA - Mavacamten for use in the treatment of hypertrophic cardiomyopathy - Google Patents
Mavacamten for use in the treatment of hypertrophic cardiomyopathyInfo
- Publication number
- SG11202000549TA SG11202000549TA SG11202000549TA SG11202000549TA SG11202000549TA SG 11202000549T A SG11202000549T A SG 11202000549TA SG 11202000549T A SG11202000549T A SG 11202000549TA SG 11202000549T A SG11202000549T A SG 11202000549TA SG 11202000549T A SG11202000549T A SG 11202000549TA
- Authority
- SG
- Singapore
- Prior art keywords
- mavacamten
- treatment
- hypertrophic cardiomyopathy
- hypertrophic
- cardiomyopathy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541591P | 2017-08-04 | 2017-08-04 | |
| US201762584537P | 2017-11-10 | 2017-11-10 | |
| US201862639922P | 2018-03-07 | 2018-03-07 | |
| US201862671585P | 2018-05-15 | 2018-05-15 | |
| PCT/US2018/045180 WO2019028360A1 (fr) | 2017-08-04 | 2018-08-03 | Mavacamten destiné à être utilisé dans le traitement de la cardiomyopathie hypertrophique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000549TA true SG11202000549TA (en) | 2020-02-27 |
Family
ID=63350605
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202112960QA SG10202112960QA (en) | 2017-08-04 | 2018-08-03 | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| SG11202000549TA SG11202000549TA (en) | 2017-08-04 | 2018-08-03 | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202112960QA SG10202112960QA (en) | 2017-08-04 | 2018-08-03 | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20200054636A1 (fr) |
| EP (1) | EP3661514A1 (fr) |
| JP (2) | JP2020529996A (fr) |
| KR (1) | KR20200035973A (fr) |
| CN (2) | CN118593507A (fr) |
| AU (2) | AU2018311974B2 (fr) |
| CA (1) | CA3071948A1 (fr) |
| IL (1) | IL272300A (fr) |
| MA (1) | MA49760A (fr) |
| MX (2) | MX2020001406A (fr) |
| RU (1) | RU2020109345A (fr) |
| SG (2) | SG10202112960QA (fr) |
| TW (1) | TW201916882A (fr) |
| UY (1) | UY37834A (fr) |
| WO (1) | WO2019028360A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3740481T3 (da) | 2018-01-19 | 2024-07-08 | Cytokinetics Inc | Dihydrobenzofuran- og indenanaloger som hjertesarkomerinhibitorer |
| WO2020005887A1 (fr) | 2018-06-26 | 2020-01-02 | Cytokinetics, Inc. | Inhibiteurs de sarcomères cardiaques |
| WO2020257609A1 (fr) * | 2019-06-21 | 2020-12-24 | MyoKardia, Inc. | Diagnostics et traitements pour une maladie cardiaque |
| CN110698415B (zh) * | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| CA3157629A1 (fr) * | 2019-11-10 | 2021-05-14 | MyoKardia, Inc. | Methodes de traitement comprenant un modulateur de myosine |
| EP4097091B1 (fr) * | 2020-01-28 | 2024-09-18 | Assia Chemical Industries Ltd. | Formes solides de mavacamten et leur procédé de préparation |
| JP2023540485A (ja) * | 2020-08-28 | 2023-09-25 | マイオカーディア，インク | ミオシンモジュレーターによる治療方法 |
| KR20230110538A (ko) | 2020-11-20 | 2023-07-24 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도 |
| US20240082248A1 (en) * | 2021-02-01 | 2024-03-14 | Dr. Reddy's Laboratories Limited | Process for preparation of mavacamten and solid state forms thereof |
| WO2022187501A1 (fr) | 2021-03-04 | 2022-09-09 | Cytokinetics, Inc. | Inhibiteurs de sarcomes cardiaques |
| CN112939876A (zh) * | 2021-03-10 | 2021-06-11 | 杭州科巢生物科技有限公司 | Mavacamten的晶型I及其制备方法 |
| WO2022189599A1 (fr) | 2021-03-12 | 2022-09-15 | Sandoz Ag | Formes cristallines de mavacamten pour le traitement de la cmh |
| AU2022312506A1 (en) * | 2021-07-16 | 2024-02-01 | Cytokinetics, Inc. | Methods for treating hypertrophic cardiomyopathy |
| WO2024097284A1 (fr) * | 2022-11-02 | 2024-05-10 | MyoKardia, Inc. | Mavacamten et ses dérivés destinés à être utilisés dans le traitement d'un dysfonctionnement atrial |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302299A (en) * | 2013-06-21 | 2023-06-01 | Myokardia Inc | Pyrimidinedione compounds against cardiac disorders |
-
2018
- 2018-08-03 MX MX2020001406A patent/MX2020001406A/es unknown
- 2018-08-03 EP EP18759209.2A patent/EP3661514A1/fr active Pending
- 2018-08-03 CN CN202410743651.3A patent/CN118593507A/zh active Pending
- 2018-08-03 TW TW107127110A patent/TW201916882A/zh unknown
- 2018-08-03 MA MA049760A patent/MA49760A/fr unknown
- 2018-08-03 SG SG10202112960QA patent/SG10202112960QA/en unknown
- 2018-08-03 RU RU2020109345A patent/RU2020109345A/ru unknown
- 2018-08-03 KR KR1020207004507A patent/KR20200035973A/ko not_active Application Discontinuation
- 2018-08-03 JP JP2020505487A patent/JP2020529996A/ja active Pending
- 2018-08-03 CA CA3071948A patent/CA3071948A1/fr active Pending
- 2018-08-03 AU AU2018311974A patent/AU2018311974B2/en active Active
- 2018-08-03 WO PCT/US2018/045180 patent/WO2019028360A1/fr unknown
- 2018-08-03 CN CN201880050881.4A patent/CN111182901A/zh active Pending
- 2018-08-03 SG SG11202000549TA patent/SG11202000549TA/en unknown
- 2018-08-06 UY UY0001037834A patent/UY37834A/es not_active Application Discontinuation
-
2019
- 2019-03-26 US US16/364,322 patent/US20200054636A1/en not_active Abandoned
-
2020
- 2020-01-28 IL IL272300A patent/IL272300A/en unknown
- 2020-02-04 MX MX2024000348A patent/MX2024000348A/es unknown
-
2022
- 2022-03-23 US US17/701,863 patent/US20220226324A1/en not_active Abandoned
- 2022-06-16 US US17/842,389 patent/US20220313695A1/en not_active Abandoned
-
2023
- 2023-02-01 JP JP2023014110A patent/JP2023065372A/ja active Pending
-
2024
- 2024-06-07 AU AU2024203872A patent/AU2024203872A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020529996A (ja) | 2020-10-15 |
| TW201916882A (zh) | 2019-05-01 |
| WO2019028360A1 (fr) | 2019-02-07 |
| RU2020109345A (ru) | 2021-09-06 |
| MX2024000348A (es) | 2024-01-26 |
| MA49760A (fr) | 2020-06-10 |
| CA3071948A1 (fr) | 2019-02-07 |
| IL272300A (en) | 2020-03-31 |
| JP2023065372A (ja) | 2023-05-12 |
| AU2018311974B2 (en) | 2024-03-07 |
| AU2024203872A1 (en) | 2024-06-27 |
| CN118593507A (zh) | 2024-09-06 |
| CN111182901A (zh) | 2020-05-19 |
| UY37834A (es) | 2019-02-28 |
| US20220226324A1 (en) | 2022-07-21 |
| SG10202112960QA (en) | 2021-12-30 |
| AU2018311974A1 (en) | 2020-02-06 |
| KR20200035973A (ko) | 2020-04-06 |
| EP3661514A1 (fr) | 2020-06-10 |
| US20200054636A1 (en) | 2020-02-20 |
| US20220313695A1 (en) | 2022-10-06 |
| MX2020001406A (es) | 2020-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272300A (en) | Mbacomtan for use in the treatment of heart muscle hypertrophy | |
| IL275482A (en) | Asketamine for the treatment of depression | |
| GB201813876D0 (en) | Treatment | |
| HK1256164A1 (zh) | 用於治療神經膠質瘤的製劑 | |
| RS65701B1 (sr) | Kompozicije za upotrebu u lečenju hipertenzije | |
| IL274363A (en) | Use of a specific siRNA against protein S for the treatment of hemophilia | |
| GB201800546D0 (en) | Treatment | |
| PL3448340T3 (pl) | Pomocniczy element aplikacyjny do opatrywania ran | |
| LT3406258T (lt) | Vaistas, skirtas podagros gydymui | |
| SI3548006T1 (sl) | Sestava za uporabo pri zdravljenju črevesnih sprememb | |
| IL289371A (en) | Methylthioninium for use in the treatment of synaptopathies | |
| IL286533A (en) | Compounds for use in the treatment of adcy5-related dyskinesia | |
| ZA202006886B (en) | R-fadrozole for use in the treatment of aldostonerism | |
| IL272658A (en) | Surface treatment | |
| PL3303486T3 (pl) | Kompozycja do obróbki powierzchni | |
| GB201513543D0 (en) | Compositions for use in the treatment of diabetes | |
| GB201814905D0 (en) | Treatment | |
| ZA201801788B (en) | Lysobactin for use in the treatment of bovine mastitis | |
| GB201718985D0 (en) | Treatment | |
| GB201713650D0 (en) | Treatment | |
| GB201706955D0 (en) | Treatment |